Protein-tyrosine-phosphatase inhibitors - Pipeline Insight, 2024

This “Protein-tyrosine-phosphatase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Protein-tyrosine-phosphatase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Protein-tyrosine-phosphatase inhibitors Understanding

Protein-tyrosine-phosphatase inhibitors: Overview

Protein tyrosine phosphatases, or PTPs, are type I transmembrane proteins, membrane associated proteins or proteins localized in nuclei. Biochemicals that inhibit PTP have many applications in biochemical and physiological research. Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. rotein tyrosine phosphorylation is regulated by balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) in mammalian cells. There are over 100 PTPs encoded in the human genome sharing a short active site ‘signature motif’. Based on the amino acid sequences of their catalytic domains, PTPs are divided into four main families: (i) class I cysteine-based PTPs, (ii) class II cysteine-based PTPs: tyrosine-specific low molecular weight phosphatases, (iii) class III cysteine-based PTPs: Cdc25 phosphatase family, and (iv) aspartic acid-based PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.

Protein-tyrosine-phosphatase inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Protein-tyrosine-phosphatase inhibitors pipeline landscape is provided which includes the disease overview and Protein-tyrosine-phosphatase inhibitors treatment guidelines. The assessment part of the report embraces, in depth Protein-tyrosine-phosphatase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Protein-tyrosine-phosphatase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Protein-tyrosine-phosphatase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Protein-tyrosine-phosphatase inhibitors.

Protein-tyrosine-phosphatase inhibitors Emerging Drugs Chapters

This segment of the Protein-tyrosine-phosphatase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Protein-tyrosine-phosphatase inhibitors Emerging Drugs

JAB-3068: Jacobio Pharmaceuticals JAB-3068 is a novel protein tyrosine phosphatase inhibitor (PTPi) with independent intellectual property rights. To date, three pharmaceutical companies worldwide are engaged in the Phase I clinical studies with anti-cancer agent in this field. JAB-3068 functions through both target therapy and immuno-oncology mechanisms. As an oral monotherapy, it has demonstrated significant anti-tumor activity; it can also promote the tumor-inhibitory immune function, offering opportunities to be combined with PD1 antibody and other drugs. In May 2020, the company entered into a license and collaboration agreement with AbbVie in relation to, amongst others, the research, development and commercialization of certain SHP2 inhibitors including JAB-3068 and JAB-3312 in May.

ERAS-601: Erasca ERAS-601, a potential best-in-class inhibitor of the Src homology region 2 domain-containing phosphatase-2 (SHP2), was licensed from Ni Kang Therapeutics, Inc. SHP2 also drives tumor cell proliferation and development of resistance. SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of resistance, thereby potentially serving as a backbone of combination therapy. It is currently being evaluated in Phase I stage of development for the treatment ofsolidtumors.

Protein-tyrosine-phosphatase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Protein-tyrosine-phosphatase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Protein-tyrosine-phosphatase inhibitors

There are approx. 20+ key companies which are developing the therapies for Protein-tyrosine-phosphatase inhibitors. The companies which have their Protein-tyrosine-phosphatase inhibitors drug candidates in the most advanced stage, i.e. phase II include Jacobio Pharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Protein-tyrosine-phosphatase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Protein-tyrosine-phosphatase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein-tyrosine-phosphatase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein-tyrosine-phosphatase inhibitors drugs.

Protein-tyrosine-phosphatase inhibitors Report Insights

• Protein-tyrosine-phosphatase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Protein-tyrosine-phosphatase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Protein-tyrosine-phosphatase inhibitors drugs?
• How many Protein-tyrosine-phosphatase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Protein-tyrosine-phosphatase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Protein-tyrosine-phosphatase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Protein-tyrosine-phosphatase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.